| Literature DB >> 22112360 |
K Kuzumoto1, N Kubota, K Ishii, K Yumoto, Y Ogiso, T Nakamura, T Katsuyama, K Oana, Y Kawakami.
Abstract
BACKGROUND: Burkholderia cepacia strains have been known to possess the capability to cause serious infections especially in neonatal intensive care units (NICUs), and their multi-drug resistances become a severe threat in hospital settings. The aim of this investigation was to evaluate the B. cepacia complex infections in the NICU in Nagano Children's Hospital, Azumino 399-8288, Japan, and to report the intervention leading to the successful cessation of the outbreak.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22112360 PMCID: PMC3351897 DOI: 10.1186/2047-783x-16-12-537
Source DB: PubMed Journal: Eur J Med Res ISSN: 0949-2321 Impact factor: 2.175
Figure 1Time course of . Each bar represents the hospitalization period of each inpatient neonate. See Table 1, for the origins, and see text in the Results section, for the backgrounds of the isolates.
Antimicrobial susceptibilities of 6 epidemic Burkholderia cepacia complex isolates (P-5, P-6, P-7. P-8. and P-9) in the NICU and 2 isolates (P-a and P-B) from unrelated wards with the neg combo 3.12J panels with the MicroScan Walkaway 40 System
| Patient No.# | Date of Isolation day/month/year | Specimen Obtained | MIC(μg/ml) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P-A | 07/09/2010 | bronchial aspirate | > 64 | > 16 | > 16 | > 16 | > 16 | > 16 | > 8 | < 1 | > 8 | > 32 | > 8 | < 2 | 2 | 2 | < 2 | > 16 | > 32 | < 8 |
| P-B | 13/09/2010 | salivary fluid | 64 | 4 | > 16 | > 16 | > 16 | > 16 | > 8 | 2 | > 8 | > 32 | > 8 | 4 | 4 | > 2 | > 2 | > 16 | > 32 | < 8 |
| P-5 | 14/09/2010 | bronchial aspirate | > 64 | 4 | > 16 | > 16 | > 16 | > 16 | > 8 | < 1 | > 8 | > 32 | > 8 | < 2 | 1 | 1 | < 2 | > 16 | > 32 | < 8 |
| P-6a | 21/09/2010 | peripheral blood | > 64 | 4 | > 16 | > 16 | > 16 | > 16 | 8 | < 1 | > 8 | > 32 | > 8 | < 2 | 1 | 1 | < 2 | > 16 | > 32 | < 8 |
| P-6b | 12/10/2010 | catheterized urine | > 64 | 8 | > 16 | > 16 | > 16 | > 16 | 8 | < 1 | > 8 | > 32 | > 8 | < 2 | 1 | 1 | < 2 | > 16 | > 32 | < 8 |
| P-7 | 14/09/2010 | bronchial aspirate | 64 | 8 | > 16 | > 16 | > 16 | > 16 | > 8 | < 1 | > 8 | > 32 | > 8 | < 2 | 1 | 1 | < 2 | > 16 | > 32 | < 8 |
| P-8 | 28/09/2010 | bronchial aspirate | > 64 | 4 | > 16 | > 16 | > 16 | > 16 | 8 | < 1 | > 8 | > 32 | > 8 | < 2 | 1 | 1 | < 2 | > 16 | > 32 | < 8 |
| P-9 | 18/01/2011 | bronchial aspirate | 64 | 8 | > 16 | > 16 | > 16 | > 16 | 8 | < 1 | > 8 | > 32 | > 8 | < 2 | < 0.5 | 0.5 | < 2 | > 16 | > 32 | < 8 |
PIPC: piperacillin, CAZ: ceftazidime, CFS: cefsulodin, CFPM: cefepime, CZOP: cefozopran, AZT: aztreonam, IPM: imipenem, MEPM: meropenem, TOB: tobramycin AMK: amikacin, GM: gentamicin, MINO: minocycline, LVFX: levofloxacin,, CPFX: ciprofloxacin, ST: sulfamethoxazole/trimethoprim, FOM: fosfomycin, C/S: cefoperazone/sulbactam, P/T: piperacillin/tazobactam #: P-A: Patient a, P-B: Patient B, both hospitalized in different wards unrelated to the NICU. as for P-5, -6, -7, -8, and -9, see text in the Results section, for the backgrounds of the isolates.
Figure 2Profiles of the genomic DNAs of 6 epidemic .